Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Account Payables (2022 - 2025)

Atara Biotherapeutics' Change in Account Payables history spans 4 years, with the latest figure at -$191000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 108.59% year-over-year to -$191000.0; the TTM value through Dec 2025 reached -$4.2 million, down 717.18%, while the annual FY2025 figure was -$4.2 million, 717.18% down from the prior year.
  • Change in Account Payables reached -$191000.0 in Q4 2025 per ATRA's latest filing, up from -$983000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.5 million in Q3 2023 to a low of -$4.6 million in Q1 2022.
  • Average Change in Account Payables over 4 years is -$993375.0, with a median of -$938500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: surged 368.34% in 2024, then crashed 261.14% in 2025.
  • A 4-year view of Change in Account Payables shows it stood at -$4.5 million in 2022, then surged by 36.85% to -$2.8 million in 2023, then skyrocketed by 179.12% to $2.2 million in 2024, then tumbled by 108.59% to -$191000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Change in Account Payables are -$191000.0 (Q4 2025), -$983000.0 (Q3 2025), and -$83000.0 (Q2 2025).